Click here to submit your thesis or research work
for consideration at GPF workshops and events.
Click here to learn more about the specific committees
and their focus areas before submitting your work.
The Greek Pharmaceutical Forum (GPF) encourages its members to actively contribute to the advancement of knowledge and innovation by submitting their theses and works to the committees they participate in. These submissions can be presented at GPF workshops and events, providing a valuable platform for sharing insights, fostering collaboration, and promoting dialogue among industry professionals.
Members are invited to submit their research, case studies, and innovative projects relevant to their respective committees. This initiative not only enhances the collective knowledge within the GPF but also allows members to showcase their expertise and contribute to the ongoing discussions that shape the future of pharmaceuticals, biotechnology, and healthcare.
The Greek Pharmaceutical Forum (GPF) comprises several specialized committees, each focusing on critical areas within the pharmaceutical and healthcare sectors. These committees provide members with opportunities to engage deeply with specific topics, collaborate on initiatives, and drive innovation. Below is an overview of each committee:
This committee focuses on the evolving landscape of pharmaceutical regulations and legislation. Members work to ensure compliance with local and international laws, advocate for policies that promote public health, and engage in discussions about regulatory challenges facing the industry. Their efforts aim to foster a regulatory environment that encourages innovation while safeguarding patient safety.
The Biotechnology committee is dedicated to advancing biotechnological innovations and applications in healthcare. Members collaborate on research and development projects, share best practices, and explore new biotechnological solutions that can improve patient outcomes. This committee plays a crucial role in bridging the gap between scientific research and practical applications in the biotech industry.
Focusing on the unique healthcare needs of children, the Paediatric committee addresses challenges related to pediatric medicine, including drug development, treatment protocols, and ethical considerations. Members work to promote research that enhances the safety and efficacy of medications for younger populations and advocate for policies that prioritize pediatric health.
The Orphan Drugs committee is dedicated to addressing the needs of patients with rare diseases. Members collaborate to promote research into orphan drugs, advocate for regulatory incentives, and raise awareness about the challenges faced by patients with rare conditions. Their goal is to ensure that innovative treatments are developed and made accessible to those who need them most.
This committee focuses on the pharmaceutical industry as a whole, addressing issues such as drug development, manufacturing practices, and market access. Members engage in discussions about industry trends, share insights on best practices, and collaborate on initiatives that enhance the overall pharmaceutical landscape.
The Advanced Therapies committee explores cutting-edge treatments such as gene therapy, cell therapy, and regenerative medicine. Members discuss the latest advancements in these fields, share research findings, and work together to address regulatory challenges associated with bringing advanced therapies to market.
Focusing on the intersection of healthcare and technology, the HealthTech committee addresses innovations that improve healthcare delivery through technology. Members explore topics such as telemedicine, digital health solutions, and data analytics in healthcare settings. Their work aims to harness technology to enhance patient care and streamline healthcare processes.
The Pharmacovigilance Risk Assessment committee is dedicated to monitoring drug safety and assessing risks associated with pharmaceutical products post-market. Members collaborate on strategies for effective pharmacovigilance practices, share findings from safety assessments, and advocate for policies that prioritize patient safety throughout the lifecycle of medications.
This committee takes a holistic approach to healthcare issues, addressing broad topics such as public health policy, healthcare access, and system efficiency. Members engage in discussions about improving healthcare delivery systems and advocate for initiatives that enhance overall population health.
The Women in Life Sciences committee aims to empower women professionals within the pharmaceutical and biotechnology sectors. Members work to promote gender diversity in leadership roles, provide mentorship opportunities, and create a supportive network for women in science. This committee strives to foster an inclusive environment where women's contributions are recognized and valued.
Each of these committees plays a vital role in advancing the mission of the GPF by fostering collaboration among professionals dedicated to improving health outcomes through innovation, research, and advocacy within their respective fields.
Patent Cliff: The expiration of patents on blockbuster drugs poses a risk of substantial revenue loss as generic competition increases.
Regulatory Pressures: New pricing regulations, such as those introduced by the Inflation Reduction Act in the U.S., threaten profit margins and may reduce incentives for research and development.
Supply Chain Disruptions: The COVID-19 pandemic exposed vulnerabilities in global supply chains, leading to increased operational complexities and costs.
Talent Shortages: A lack of skilled professionals in STEM fields hampers innovation and operational efficiency as demand for expertise grows.
Rising Costs: Inflation has increased expenses across the industry, putting pressure on profit margins and necessitating cost-cutting measures.
Increased Competition: The market is becoming more competitive with a surge in research for rare diseases and personalized medicine, requiring companies to navigate emerging technologies.